Stratification Approach for Splenic Marginal Zone Lymphoma Based on Hemoglobin, Platelet Count, High LDH and Extrahilar Lymphadenopathy: The HPLL/ABC System

Abstract 1583 Splenic Marginal Zone Lymphoma (SMZL) is a distinct lymphoma included in the WHO 2008 classification. Ann Arbor staging system is not adequate to stratify SMZL patients into risk groups, as blood and bone marrow are usually involved. Further, there are neither established criteria for...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2011-11, Vol.118 (21), p.1583-1583
Main Authors: Montalban, Carlos, Abraira, Victor, Arcaini, Luca, Domingo-Domenech, Eva, Guisado-Vasco, Pablo, Iannitto, Emilio, Mollejo, Manuela, Matutes, Estella, Ferreri, Andrés JM, Salar, Antonio, Carpaneto, Andrea, Pérez, Ricardo, Bello, Jose Luis, Hernandez, Miguel, Caballero, Dolores, Piris, Miguel A.
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract 1583 Splenic Marginal Zone Lymphoma (SMZL) is a distinct lymphoma included in the WHO 2008 classification. Ann Arbor staging system is not adequate to stratify SMZL patients into risk groups, as blood and bone marrow are usually involved. Further, there are neither established criteria for starting treatment nor gold standard treatment. Herein we report an international retrospective study on 593 SMZL patients aimed to identify which factors could influence starting treatment and which could allow stratify risk categories. Logistic regression was used to identify the factors that have conditioned treatment in the whole series and Cox regression for factors influencing Lymphoma Specific Survival (LSS) in a training set of 336 patients. The variables used were age, hemoglobin level and platelet count (as continuous variables) and sex, low albumin serum level (
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V118.21.1583.1583